Is multiple myeloma a primary bone cancer?

No. Multiple myeloma is a blood and immune system cancer arising from antibody-producing plasma cells inside the spongy bone marrow. Although rogue plasma cells release signals that dissolve surrounding bone tissue—causing osteolytic holes (≥ 5 mm) and fractures—the disease is treated systemically with targeted drugs and immunotherapies rather than surgical bone removal.

What is the difference between M-protein and Bence-Jones protein?

M-protein (monoclonal protein or M-spike) is an intact, non-functional antibody composed of two heavy chains (such as IgG or IgA) and two light chains (kappa [κ] or lambda [λ]) circulating in the blood. Bence-Jones protein refers strictly to unattached, low-molecular-weight free light chains that pass through the kidney filters and appear in a 24-hour urine collection.

Why do I need active treatment if I feel completely healthy but meet a SLiM biomarker?

The three SLiM biomarkers—bone marrow clonal plasma cells ≥ 60%, involved/uninvolved serum free light chain ratio ≥ 100 (with involved FLC ≥ 100 mg/L [≥ 10 mg/dL]), or > 1 focal bone marrow lesion (≥ 5 mm) on MRI—carry an 80% or higher risk of causing irreversible fractures or kidney failure within 2 years. Treating at the SLiM stage stops organ damage before it strikes.

Does everyone with MGUS or Smoldering Multiple Myeloma develop active myeloma?

No. MGUS progresses at a steady, low rate of about 1% per year, meaning roughly 90% of individuals with MGUS never develop active myeloma. Smoldering Multiple Myeloma (SMM) carries a front-loaded risk of about 10% per year during the first 5 years, which drops to 3% per year in years 6 to 10 and 1% to 2% per year after year 10.

When should a patient with MGUS, SMM, or myeloma be screened for AL amyloidosis?

Immediate screening is needed if you develop persistent foamy urine (24-hour urine albumin ≥ 0.5 g/24h), unexplained shortness of breath or ankle swelling (NT-proBNP > 332 ng/L or elevated troponin), bilateral carpal tunnel syndrome, severe dizziness upon standing, an enlarged tongue with tooth indentations, or purple bruising around the eyes.

Can I have active multiple myeloma if my blood M-spike reads zero?

Yes. Approximately 15% to 20% of patients have Light-Chain Only myeloma (which produces detached κ or λ free light chains without an intact M-spike on standard SPEP), and 1% to 3% have Non-Secretory or Oligo-Secretory myeloma. These subtypes are tracked using serum free light chain assays, 24-hour urine electrophoresis, bone marrow biopsies, and whole-body PET-CT or MRI.

Back to Guidelines

newly-diagnosed

What Is Multiple Myeloma? Causes, Stages, and Early Signs

Name: What Is Multiple Myeloma? Causes, Stages, and Early Signs
Creator: CMDN Editorial Team

How it develops, when you actually need treatment, and red flags not to miss

Medical Disclaimer: This guide is synthesized from international clinical consensus guidelines and peer-reviewed literature. It is for educational purposes only and does not substitute for professional medical advice. Always consult your oncology team regarding diagnostic and treatment decisions.

💡 The Short Answer

Multiple myeloma is a treatable hematologic cancer of bone marrow plasma cells (≥ 10% clonal plasma cells) that evolves from precursor states—MGUS (1% per year progression risk) and Smoldering Multiple Myeloma (SMM, 10% per year in years 1 to 5)—into active disease. Under international IMWG and NCCN (v2.2027) standards, systemic therapy begins only when rogue plasma cells cause CRAB end-organ damage, trigger a SLiM biomarker (marrow ≥ 60%, free light chain ratio ≥ 100, or > 1 MRI lesion), or deposit misfolded light chains in AL amyloidosis.

Why This Matters

Receiving a diagnosis involving abnormal plasma cells or monoclonal proteins often leaves patients and caregivers facing three major sources of confusion:

Mistaking multiple myeloma for terminal bone cancer: Because myeloma frequently causes back pain or lytic bone lesions on orthopedic scans, families often mistake it for primary bone sarcoma or metastatic solid cancer.
Wondering why some patients start therapy immediately while others watch and wait: Without understanding the SLiM-CRAB dividing line, it is hard to see why precursor stages (MGUS and low-risk SMM) are safely monitored without chemotherapy.
Overlooking early organ signals of coexisting AL amyloidosis: In 10% to 15% of patients, misfolded light chains quietly injure the kidneys, heart, or nerves even when bone marrow plasma cell counts look low.

This guide explains how clonal plasma cells behave in plain terms, how doctors apply the SLiM-CRAB criteria to diagnose active disease, how myeloma evolves across its three-stage continuum, and how to spot AL amyloidosis early.

📖 Key Terms in Plain English

Before reviewing your diagnostic reports, here is a plain-language translation of six core terms used in every myeloma consultation:

Term	Plain-English Meaning
Plasma Cells	Mature white blood cells living inside the bone marrow (the spongy center of bones) that normally manufacture diverse antibodies to fight infections.
M-Protein (M-Spike)	Short for monoclonal protein (or paraprotein)—identical, non-functional antibodies mass-produced by a single malignant plasma cell clone.
Free Light Chains (sFLC)	Small, unattached antibody fragments (kappa [κ] or lambda [λ]) circulating in the blood; when filtered into urine, they are called Bence-Jones proteins.
CRAB Criteria	The 4 classic signs of active organ injury: Calcium elevation, Renal (kidney) insufficiency, Anemia, and Bone lytic lesions.
SLiM Biomarkers	3 early biological triggers (Sixty percent marrow plasma cells, Light chain ratio ≥ 100, MRI focal lesions > 1) indicating an ≥ 80% risk of organ damage within 2 years.
AL Amyloidosis	A related disorder where misfolded light chains (usually λ) clump into insoluble fibrils and deposit inside the heart, kidneys, liver, or nerves.

1. What Is Multiple Myeloma? When Your Antibody Factory Goes Rogue

Healthy Plasma Cells vs. Malignant Clonal Proliferation

Think of your bone marrow as your body's immune defense factory. In a healthy person, mature B-lymphocytes develop into plasma cells that produce a diverse mix (polyclonal repertoire) of antibodies to neutralize bacteria and viruses.

In multiple myeloma, a single plasma cell acquires genetic mutations and begins cloning itself without restraint:

Crowding out normal blood production: Malignant clonal plasma cells multiply inside the marrow cavity, squeezing out healthy stem cells that produce red blood cells, infection-fighting white blood cells, and platelets.
Flooding the bloodstream with a single useless protein: Instead of making helpful antibodies, the malignant clone secretes vast amounts of one identical immunoglobulin (M-protein) or detached free light chains while suppressing normal immune antibodies (immunoparesis).

Tip

Prognosis in the Modern Era: A Manageable Chronic Condition

With the arrival of anti-CD38 monoclonal antibodies, proteasome inhibitors, immunomodulatory drugs, bispecific antibodies, and CAR-T cell therapies, median survival in multiple myeloma has more than doubled—from 3 to 5 years decades ago to 7 to 10+ years today—with a growing subset of patients achieving long-term functional cure (sustained Minimal Residual Disease [MRD] negativity).

Understanding Antibody Structure & Myeloma Subtypes

Every complete antibody molecule is shaped like the letter "Y" and consists of 2 identical heavy chains (IgG, IgA, IgM, IgD, or IgE) paired with 2 identical light chains (kappa [κ] or lambda [λ]). Your myeloma is named after the specific chains your clone secretes:

Myeloma Subtype	What the Clone Secretes	Share of Cases	Key Clinical & Monitoring Feature
IgG Myeloma	Intact IgG antibody (`κ` or `λ`)	50%–65%	Most common subtype; shows a clear M-spike in the gamma region on serum protein electrophoresis (SPEP).
IgA Myeloma	Intact IgA antibody (`κ` or `λ`)	15%–20%	Second most common; often migrates in the beta region on SPEP and has a slightly higher tendency for soft-tissue growth.
Light-Chain Only	Detached `κ` or `λ` free light chains only (no heavy chain)	15%–20%	Shows zero intact M-spike on routine SPEP; must be tracked via Serum Free Light Chain (sFLC) and 24-hour urine (UPEP); carries higher kidney risk.
Non- / Oligo-Secretory	Little or no detectable M-protein in blood or urine	1%–3%	Baseline M-protein is absent or below standard measurable thresholds; monitored via bone marrow biopsies and PET-CT or MRI scans.
Rare Subtypes (`IgD`, `IgE`, `IgM`)	Intact IgD, IgE, or IgM paraprotein	< 2%	Rare variants; `IgD` often pairs with `λ` light chains and kidney strain, while `IgM` myeloma must be distinguished from Waldenström macroglobulinemia.

What This Means for You: Knowing your exact subtype prevents dangerous monitoring mistakes. If you have IgG or IgA myeloma, your doctor tracks both your blood M-spike and free light chains. If you have Light-Chain Only myeloma, your M-spike will always read zero—meaning you must watch your serum free light chains and 24-hour urine protein at every checkup.

Data Sources: NCCN Guidelines v2.2027; IMF Patient Handbook; IMWG Consensus Guidelines.

2. How Myeloma Damages the Body: The SLiM-CRAB Diagnostic Criteria

Under international IMWG (2014) and NCCN (Version 2.2027) criteria, a diagnosis of Active Multiple Myeloma requiring systemic therapy requires ≥ 10% clonal bone marrow plasma cells (or a biopsy-proven plasmacytoma) plus at least 1 Myeloma-Defining Event from either the CRAB features or SLiM biomarkers below.

Part A: The "CRAB" Features (Active End-Organ Damage)

CRAB Feature	Official Diagnostic Cutoff (Dual Units)	How Clonal Cells Cause the Damage & Common Symptoms
C — Calcium Elevation	Serum calcium > 11.0 mg/dL (> 2.75 mmol/L); OR > 1.0 mg/dL (> 0.25 mmol/L) above normal	Myeloma cells stimulate bone-resorbing cells (osteoclasts), dumping excess calcium from bone matrix into the blood. Causes severe thirst, nausea, constipation, and confusion.
R — Renal Insufficiency	Serum creatinine > 2.0 mg/dL (> 177 μmol/L); OR creatinine clearance (CrCl/eGFR) < 40 mL/min	Excess free light chains overwhelm kidney tubules and bind with Tamm-Horsfall protein to form obstructive plugs (myeloma cast nephropathy). Often silent until fatigue or swelling develops.
A — Anemia	Hemoglobin < 10.0 g/dL (< 100 g/L); OR > 2.0 g/dL (> 20 g/L) below the lower limit of normal	Clonal plasma cells crowd the marrow niche and release inflammatory signals that suppress red blood cell production. Causes persistent fatigue, pallor, and shortness of breath on exertion.
B — Bone Lesions	≥ 1 osteolytic lesion (≥ 5 mm) on whole-body low-dose CT, FDG-PET/CT, or skeletal X-ray	Myeloma activates bone-eating osteoclasts (via RANKL) while blocking bone-rebuilding osteoblasts (via DKK-1). Causes deep back or rib pain and pathologic fractures.

What This Means for You: If you meet any single CRAB criterion proven to be caused by your plasma cell disorder, organ damage is already underway—confirming Active Multiple Myeloma that requires immediate systemic treatment. (Note: Diffuse osteoporosis or age-related bone thinning alone without a discrete ≥ 5 mm lytic hole does not fulfill the CRAB bone criterion.)

Part B: The "SLiM" Biomarkers (Defusing the Bomb Before Organ Damage Strikes)

If you have zero CRAB symptoms, doctors check the three SLiM biomarkers. Each SLiM feature identifies ultra-high-risk disease that carries an ≥ 80% probability of progressing to CRAB organ damage within 2 years:

SLiM Biomarker	Official Diagnostic Cutoff	Plain-English Translation
S — Sixty Percent	Clonal bone marrow plasma cells ≥ 60% on biopsy	Nearly two-thirds of the bone marrow cavity is packed with malignant plasma cells; marrow failure is imminent.
Li — Light Chain Ratio	Involved / uninvolved serum FLC ratio ≥ 100 (with involved FLC ≥ 100 mg/L [≥ 10 mg/dL])	The tumor-produced light chain is at least 100 times higher than the normal light chain, placing the kidneys in acute danger of tubular blockage.
M — MRI Focal Lesions	> 1 focal lesion (≥ 5 mm) inside the bone marrow on spine or whole-body MRI	Even before the outer cortical bone shell breaks on a CT scan, MRI detects 2 or more distinct tumor nodules growing inside the marrow.

What This Means for You: Think of SLiM as catching a fire while it is still smoldering inside the walls. Even if you feel completely energetic today, meeting any single SLiM cutoff upgrades your diagnosis from smoldering myeloma to Active Multiple Myeloma so treatment can protect your kidneys and spine before permanent injury occurs.

Data Sources: IMWG 2014 Diagnostic Criteria; NCCN Guidelines v2.2027 (MYEL-B).

3. How Does Myeloma Evolve? From MGUS to Smoldering Myeloma to Active Disease

The Three-Stage Biological Continuum

Nearly every case of active multiple myeloma develops gradually across a multi-step biological continuum over years or decades:

Stage 1: MGUS (Monoclonal Gammopathy of Undetermined Significance): The quiet "Dormant Seed" stage. A small plasma cell clone acquires an initial primary genetic hit—either hyperdiploidy (extra odd-numbered chromosomes such as 3, 5, 7, 9, 11, 15, 19, or 21) or a primary IGH chromosome translocation on chromosome 14q32 (t(11;14), t(4;14), t(14;16), or t(14;20)). It causes no symptoms and is typically found incidentally on routine lab work.
Stage 2: Smoldering Multiple Myeloma (SMM): The intermediate "Expanding Clone" stage. The clonal plasma cell population expands to 10%–59% of the bone marrow (or M-protein reaches ≥ 3.0 g/dL [≥ 30 g/L]), but the patient still has zero SLiM-CRAB organ damage.
Stage 3: Active Multiple Myeloma: The "Active Disease" stage. Subclones acquire secondary genetic hits—such as del(17p) / TP53 mutation, chromosome 1q21 gain or amplification (+1q), del(1p32), or MYC rearrangements (8q24)—that accelerate proliferation and trigger SLiM-CRAB events. (In advanced stages, myeloma clones can become independent of the bone marrow microenvironment, forming soft-tissue tumors called Extramedullary Disease [EMD] or entering the bloodstream as Plasma Cell Leukemia [PCL] when circulating plasma cells reach ≥ 5%.)

Comparing MGUS, Smoldering Myeloma, and Active Myeloma in One Table

Disease Stage	Bone Marrow & M-Protein Cutoffs	SLiM-CRAB or Amyloid Damage?	Annual Progression Risk	Standard Guideline Action (NCCN v2.2027)
1. MGUS	• Serum M-protein < 3.0 g/dL (< 30 g/L); AND • Clonal bone marrow plasma cells < 10%	❌ None	1% per year (steady, constant linear risk over a lifetime)	❌ Do NOT treat. Active surveillance with labs every 6 to 12 months.
2. Smoldering (SMM)	• Serum M-protein ≥ 3.0 g/dL (≥ 30 g/L) OR urine M-protein ≥ 500 mg/24h; AND/OR • Clonal marrow plasma cells 10%–59%	❌ None	• Years 1–5: 10% per year; • Years 6–10: 3% per year; • After Year 10: 1%–2% per year	• Low/Int Risk: ✅ Active surveillance every 3 to 6 months; • High Risk (`20/2/20`): Daratumumab (Cat 1), clinical trial, or close monitoring.
3. Active Myeloma	• Clonal marrow plasma cells ≥ 10% (or biopsy-proven plasmacytoma)	✅ ≥ 1 SLiM-CRAB feature present	100% (already active disease)	🚨 Start systemic therapy plus bone-targeted protection (`zoledronic acid` or `denosumab`).

What This Means for You: Look at how differently MGUS and SMM behave over time. MGUS has a flat 1% per year progression rate—meaning roughly 90% of people with MGUS will never progress to myeloma. Smoldering Myeloma carries its highest danger during the first 5 years (10% per year), where doctors apply the IMWG / Mayo 20/2/20 risk model (Bone marrow plasma cells > 20%, M-protein > 2.0 g/dL [> 20 g/L], and Free Light Chain ratio > 20) to identify high-risk SMM patients who may benefit from early intervention. If an SMM patient remains stable past 5 to 10 years, their annual risk slows down toward MGUS levels.

Data Sources: NCCN Guidelines v2.2027; IMWG 2014 Criteria; Mayo Clinic mSMART 4.0.

4. Crucial Early Warning: Recognizing Coexisting Light-Chain (AL) Amyloidosis

Why a Small Plasma Cell Clone Can Cause Major Organ Damage

In 10% to 15% of multiple myeloma patients—and in a critical subset of patients initially labeled as having MGUS or SMM—the clonal plasma cells secrete unstable free light chains (predominantly lambda [λ] in 75%–90% of cases) that misfold into insoluble protein fibrils.

Rather than being harmlessly excreted, these misfolded fibrils deposit in the extracellular spaces of the heart, kidneys, liver, gastrointestinal tract, and nerves, causing Systemic Light-Chain (AL) Amyloidosis.

Warning

AL Amyloidosis Overrides Watch and Wait

A patient can have fewer than 10% plasma cells in the bone marrow and zero CRAB bone lesions, yet suffer progressive heart or kidney failure from AL amyloidosis. Whenever systemic AL amyloidosis is confirmed, active surveillance is strictly contraindicated—immediate anti-plasma-cell therapy (such as Daratumumab + CyBorD) is required to halt light-chain production.

Early Clinical Red Flags & Biomarker Screening Table

Because early amyloid deposits often mimic ordinary age-related complaints, patients and doctors must watch closely for these organ-specific red flags:

Target Organ	Early Clinical Red-Flag Symptoms	Mandatory Screening Biomarkers & Tests
Kidneys (70% of cases)	Persistent foamy urine (resembling beer foam that does not dissipate) accompanied by swelling in the ankles, legs, or around the eyes (nephrotic edema).	24-hour urine total protein and albumin ≥ 0.5 g/24h (predominantly albumin leakage, unlike classic myeloma light-chain cast nephropathy).
Heart (50%–60% of cases)	Shortness of breath climbing stairs, inability to lie flat at night, unexplained heart failure with preserved ejection fraction (HFpEF), or fainting spells.	Serum NT-proBNP > 332 ng/L (high-risk cutoff ≥ 1,800 ng/L) and Cardiac Troponin T/I; Echocardiogram showing thickened ventricular walls (> 12 mm) with low ECG voltage.
Nerves (20%–30% of cases)	Bilateral carpal tunnel syndrome (often preceding diagnosis by years), symmetric numbness or tingling in the feet, or severe dizziness when standing up (orthostatic hypotension).	Orthostatic blood pressure measurements (lying vs. standing); nerve conduction studies; serum dFLC (difference between involved and uninvolved FLC ≥ 180 mg/L marks high burden).
Soft Tissue, Tongue & Liver	Enlarged, stiff tongue with lateral tooth indentations (macroglossia), spontaneous purple bruising around the eyelids ("raccoon eyes" / periorbital purpura), or unexplained liver enlargement.	Focused physical examination; serum Alkaline Phosphatase (ALP) > 1.5× upper limit of normal; GI motility evaluation for alternating diarrhea and constipation.

What This Means for You: If you are being monitored for MGUS or SMM—or newly diagnosed with myeloma—and notice frothy urine, new breathlessness, ankle swelling, dizziness upon standing, or eyelid bruising, alert your hematologist immediately. Requesting three simple screening tests—a 24-hour urine albumin check, blood NT-proBNP, and cardiac troponin—can catch AL amyloidosis months before irreversible heart or kidney injury occurs.

The 3-Step Minimally Invasive Biopsy Pathway to Confirm AL Amyloidosis

Confirming AL amyloidosis rarely requires invasive heart or kidney surgery at the start. Guidelines follow a streamlined 3-step diagnostic pathway:

Step 1: Abdominal Fat Pad Aspirate + Bone Marrow Biopsy: Doctors first perform a simple needle aspiration of fat just beneath the belly skin (subcutaneous fat pad biopsy) combined with your bone marrow core biopsy. Together, these two minimally invasive samples detect 85% to 90% of systemic AL amyloidosis cases. (A direct kidney, heart, or GI biopsy is performed only if both screening biopsies are negative while clinical suspicion remains high.)
Step 2: Congo Red Staining under Polarized Light: Pathologists stain the biopsy tissue with Congo red dye. When viewed under a polarized light microscope, true amyloid fibrils display a signature "apple-green birefringence."
Step 3: Mass Spectrometry Subtyping (Gold Standard): Because other proteins (such as age-related wild-type or hereditary transthyretin [ATTR]) can also form Congo-red-positive amyloid, the lab must perform Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) on laser-microdissected tissue to prove definitively that the fibrils consist of kappa or lambda immunoglobulin light chains before initiating chemotherapy.

Data Sources: NCCN Guidelines for Systemic Light Chain Amyloidosis; NCCN Multiple Myeloma Guidelines v2.2027; Mayo Clinic Consensus Guidelines.

Common Pitfalls to Avoid

Pitfall 1: Confusing Multiple Myeloma with Surgical "Bone Cancer"

❌ The Pitfall: Assuming that because myeloma causes punched-out bone holes and spinal fractures, it is a primary bone sarcoma or metastatic bone tumor requiring surgical resection.

✅ The Right Move: Understand that multiple myeloma is a hematologic cancer of bone marrow plasma cells. Systemic targeted and immune therapies managed by a hematologist-oncologist—paired with bone-strengthening agents (zoledronic acid or denosumab)—heal and stabilize the skeleton from the inside out.

Pitfall 2: Assuming a Zero Blood "M-Spike" Rules Out Myeloma or Relapse

❌ The Pitfall: Relying solely on routine Serum Protein Electrophoresis (SPEP) and concluding that an M-spike of "0" means no myeloma is present.

✅ The Right Move: Roughly 15% to 20% of patients have Light-Chain Only myeloma (which secretes detached κ or λ chains without an intact M-spike), and 1% to 3% have Non-Secretory disease. Always combine SPEP with a Serum Free Light Chain (sFLC) panel, 24-hour urine electrophoresis (UPEP/UIFE), and cross-sectional imaging.

Pitfall 3: Delaying Treatment When You Have a "SLiM" Biomarker Because You Feel Fine

❌ The Pitfall: Postponing systemic therapy because you have zero bone pain, normal hemoglobin, and normal kidney function—even though your bone marrow plasma cells are ≥ 60% or your free light chain ratio is ≥ 100.

✅ The Right Move: Treat SLiM biomarkers with the same urgency as CRAB organ damage. Over 80% of untreated SLiM-positive patients suffer fractures, anemia, or renal failure within 24 months.

Pitfall 4: Dismissing Frothy Urine or Breathlessness as "Normal Aging" in MGUS or SMM

❌ The Pitfall: Reassuring yourself that stable M-protein numbers mean your new ankle swelling, foamy urine, or shortness of breath cannot be related to your plasma cells.

✅ The Right Move: Screen promptly for Systemic AL Amyloidosis using 24-hour urine albumin, NT-proBNP, and cardiac troponin, followed by Congo red staining of an abdominal fat pad aspirate and bone marrow biopsy.

Pitfall 5: Taking Over-the-Counter NSAID Painkillers for Myeloma Bone Pain

❌ The Pitfall: Using non-steroidal anti-inflammatory drugs (NSAIDs such as ibuprofen, naproxen, diclofenac, or celecoxib) to manage back or rib pain.

✅ The Right Move: Strictly avoid all NSAIDs. Myeloma kidneys are already vulnerable to free light chain filtration, and NSAIDs constrict renal blood flow, frequently precipitating acute kidney failure. Ask your hematologist for kidney-safe pain control and bone-modifying therapy.

Summary: Your Quick Decision Guide

IMWG & NCCN Diagnostic Continuum

From Precursor Clones to Active Myeloma

1. MGUS

~1% / yr risk

Marrow < 10% · M-Protein < 3.0 g/dL

SLiM-CRABAbsent (Zero damage)

Standard ActionObserve every 6–12 mos

2. Smoldering (SMM)

~10% / yr (yrs 1–5)

Marrow 10%–59% or M-Protein ≥ 3.0 g/dL

SLiM-CRABAbsent (Zero damage)

Standard Actionq3–6m labs or high-risk trial

3. Active Myeloma

SLiM-CRAB Positive

Marrow ≥ 10% + ≥ 1 Myeloma-Defining Event

SLiM-CRAB≥ 1 Criterion Met

Standard ActionImmediate systemic therapy

AL Amyloidosis Override: Foamy urine, high NT-proBNP, or neuropathy requires Congo red biopsy & immediate therapy—even if marrow is < 10%.

The SLiM-CRAB Boundary: Zero SLiM-CRAB features = active surveillance or trial; meeting even 1 feature mandates systemic therapy.

Core Takeaways for Patients and Families

Know your exact subtype and tracking marker: Whether your clone makes intact IgG/IgA (tracked by SPEP M-spike) or free light chains only (tracked by sFLC and 24-hour urine) determines how your doctor monitors your disease.
Use SLiM-CRAB as your action boundary: Precursor states (MGUS and low/intermediate-risk SMM) without SLiM-CRAB damage are safely monitored without chemotherapy, whereas meeting even 1 SLiM or CRAB criterion demands immediate treatment.
Stay vigilant for AL amyloidosis red flags: Regardless of how small your plasma cell clone looks, persistent foamy urine, unexplained shortness of breath, bilateral carpal tunnel syndrome, orthostatic dizziness, or periorbital bruising requires prompt biomarker and Congo red biopsy screening.
Insist on modern cross-sectional imaging: Plain X-rays miss up to half of early bone lesions; always use whole-body low-dose CT, FDG-PET/CT, or whole-body/spine MRI at baseline and when evaluating new bone pain.

If your diagnostic numbers sit near a borderline threshold—or if you experience unexplained kidney, cardiac, or nerve symptoms alongside a monoclonal protein—consider seeking a comprehensive evaluation at a specialized Multiple Myeloma and Amyloidosis Center.

Next Steps & Related Decision Guides

Precursor Monitoring & Risk Stratification: If you were diagnosed with MGUS or asymptomatic smoldering disease, see our MGUS & Smoldering Myeloma Guide to understand monitoring schedules and the 20/2/20 risk model.
Disease Staging & Genetics: Learn how R-ISS/R2-ISS staging and cytogenetic abnormalities (del(17p), t(4;14), 1q21+) define your individual prognosis in our Myeloma Staging & Classification Guide and High-Risk Myeloma Guide.
Deciphering Your Lab Work: Need help understanding your SPEP, immunofixation, and bone marrow biopsy numbers? Read our Understanding Lab Reports Guide and Bone Marrow Biopsy Guide.
Clinical Trials Navigation: Search active Phase 1 to 3 studies for newly diagnosed and precursor patients across leading academic centers in the CMDN Clinical Trials Navigator.

References

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Multiple Myeloma, Version 2.2027.
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Systemic Light Chain Amyloidosis.
Rajkumar SV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology. 2014;15(12):e538-e548.
Mayo Clinic Myeloma, Amyloidosis, and Dysproteinemia Group. mSMART 4.0: Consensus Guidelines for Risk Stratification and Management of Multiple Myeloma and Precursor States.
Kyle RA, et al. Clinical course and prognosis of monoclonal gammopathy of undetermined significance and smoldering (asymptomatic) multiple myeloma. New England Journal of Medicine.
International Myeloma Foundation (IMF) & Multiple Myeloma Research Foundation (MMRF). Patient Handbook and Disease Overview Guidelines.

This clinical decision guide is synthesized from international consensus guidelines and peer-reviewed literature for educational purposes only. It does not substitute for professional medical care. Consult your treating hematology-oncology team regarding diagnostic and treatment decisions.

Your myeloma care companion

CMDN Care · Myeloma Companion

Organize your lab reports, follow biomarker trends, and prepare questions for your care team with CMDN’s English-language companion for myeloma patients and caregivers.

Open CMDN Care How CMDN Care works

Lab report OCR

Review results extracted from your reports.

Biomarker trends

Keep follow-up results in one place.

Visit preparation

Bring your questions to your care team.

Your share could light up hope for another patient 💛

FAQs

Is multiple myeloma a primary bone cancer?: No. Multiple myeloma is a blood and immune system cancer arising from antibody-producing plasma cells inside the spongy bone marrow. Although rogue plasma cells release signals that dissolve surrounding bone tissue—causing osteolytic holes (≥ 5 mm) and fractures—the disease is treated systemically with targeted drugs and immunotherapies rather than surgical bone removal.
What is the difference between M-protein and Bence-Jones protein?: M-protein (monoclonal protein or M-spike) is an intact, non-functional antibody composed of two heavy chains (such as IgG or IgA) and two light chains (kappa [κ] or lambda [λ]) circulating in the blood. Bence-Jones protein refers strictly to unattached, low-molecular-weight free light chains that pass through the kidney filters and appear in a 24-hour urine collection.
Why do I need active treatment if I feel completely healthy but meet a SLiM biomarker?: The three SLiM biomarkers—bone marrow clonal plasma cells ≥ 60%, involved/uninvolved serum free light chain ratio ≥ 100 (with involved FLC ≥ 100 mg/L [≥ 10 mg/dL]), or > 1 focal bone marrow lesion (≥ 5 mm) on MRI—carry an 80% or higher risk of causing irreversible fractures or kidney failure within 2 years. Treating at the SLiM stage stops organ damage before it strikes.
Does everyone with MGUS or Smoldering Multiple Myeloma develop active myeloma?: No. MGUS progresses at a steady, low rate of about 1% per year, meaning roughly 90% of individuals with MGUS never develop active myeloma. Smoldering Multiple Myeloma (SMM) carries a front-loaded risk of about 10% per year during the first 5 years, which drops to 3% per year in years 6 to 10 and 1% to 2% per year after year 10.
When should a patient with MGUS, SMM, or myeloma be screened for AL amyloidosis?: Immediate screening is needed if you develop persistent foamy urine (24-hour urine albumin ≥ 0.5 g/24h), unexplained shortness of breath or ankle swelling (NT-proBNP > 332 ng/L or elevated troponin), bilateral carpal tunnel syndrome, severe dizziness upon standing, an enlarged tongue with tooth indentations, or purple bruising around the eyes.
Can I have active multiple myeloma if my blood M-spike reads zero?: Yes. Approximately 15% to 20% of patients have Light-Chain Only myeloma (which produces detached κ or λ free light chains without an intact M-spike on standard SPEP), and 1% to 3% have Non-Secretory or Oligo-Secretory myeloma. These subtypes are tracked using serum free light chain assays, 24-hour urine electrophoresis, bone marrow biopsies, and whole-body PET-CT or MRI.

References used for this guide

Sincere thanks to the following authoritative institutions
for their academic support:

Lighting the hope of survival
for myeloma patients globally

Medical Disclaimer: Information provided on this site is synthesized from authoritative consensus guidelines for educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult your qualified healthcare team regarding clinical decisions.

This article is reviewed and published by the CMDN Editorial Team

Last updated: 2026-10-27

Get Support